Bevacizumab in combination with metronomic chemotherapy in patients with anthracycline- and taxane-refractory breast cancer

Journal of Chemotherapy

Volumn 20, Issue 5, 2008, Pages 632-639

  García Sáenz, José A ^a   Martin M ^a   Calles, A ^a   Bueno, C ^a   Rodriguez L ^a   Bobokova, J ^a   Custodio, A ^a   Casado, A ^a   Diaz Rubio E ^a  

^a HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Antiangiogenic; Bevacizumab; Breast cancer; Metronomic; Trastuzumab; VEGF

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BEVACIZUMAB; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; METHOTREXATE; TAXANE DERIVATIVE; TRASTUZUMAB;

ADULT; AGED; ALOPECIA; ANEMIA; ANTIANGIOGENIC THERAPY; ARTICLE; ASTHENIA; BLOOD TOXICITY; BONE METASTASIS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE ACTIVITY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; EPISTAXIS; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; GINGIVA BLEEDING; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; LIVER METASTASIS; LOADING DRUG DOSE; LUNG EMBOLISM; LUNG METASTASIS; MUCOSA INFLAMMATION; NAUSEA AND VOMITING; NEUTROPENIA; OVERALL SURVIVAL; PANCYTOPENIA; PROTEIN EXPRESSION; PROTEINURIA; SIDE EFFECT; SOFT TISSUE METASTASIS; SURVIVAL TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 57049164414     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2008.20.5.632     Document Type: Article

References (50)

1. National Cancer Institute of Canada: Canadian Cancer Statistics 1996. Toronto, Canada: 1996, 21-23.
2. Jemal A, Tiwari RC, Murray T et al. Cancer statistics. CA Cancer J Clin 2004; 54: 8-29.
3. Greenberg PA, Hortobagyi GN, Smith TL et al. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-2205.
4. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974-984.
5. Esteva FJ, Valero V, Pusztai L et al. Chemotherapy of metastatic breast cancer: what to expect in 2001 and beyond. Oncologist 2001; 6: 133-146.
6. Hudis CA. Current status and future directions in breast cancer therapy. Clin Breast Cancer 2003; 4: S70-5.
7. Giordano SH, Buzdar AU, Smith TL et al. Is breast cancer survival improving? Cancer 2004; 100: 44-52.
8. Hobday TJ, Perez EA. Molecularly targeted therapies for breast cancer. Cancer Control 2005; 12: 73-81.
9. Folkman J. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763.
10. Ferrara N, Garber NH, Le Couter J. The biology of VEGF and its receptors. Nat Med 2003; 9: 669-676.
11. Toi M, Kondo S, Suzuhi H et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996; 77: 1101-1106.
12. Price DJ, Miratern T, Jiang S et al. Role of vascular endothelial growth factor in stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ 2001; 12: 129-135.
13. Foekens JA, Peters HA, Grebenchtchikov N et al. High tumor levels of vascular endothelial growth factor predict poor response to systemic therapy in advanced breast cancer. Cancer Res 2001; 61: 5407-5414.
14. Bevacizumab. Anti-VEGF monoclonal antibody, Avastin, rHuMAb VEGF. Drugs R D 2002; 3: 28-30.
15. Cobleigh MA, Langmuir VK, Sledge GW et al. A phase I/II dose-escalation trial of bevacizumab in previously treated metastatic breast cancer. Semin Oncol 2003; 30: 117-124.
16. Miller KD, Wang M, Gralow J, et al. First-line bevacizumab and paclitaxel in patients with locally recurrent or metastatic breast cancer: a randomized, phase III trial coordinated by the Eastern Cooperative Oncology Group (E2100). Eur J Cancer Supp 2005; 3: 77.
17. Hanahan D, Bergers G, Bergsland E. Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 2000; 105: 1045.
18. Miller KD, Sweeney C, Sledge GW. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 2001; 19: 1195-1206.
19. Klement G, Baruchel S, Rak J et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: 15-24.
20. Eberhard A, Chalet S, Goede V et al. Heterogeneity of angiogenesis and blood vessel maturation in human tumor: implications for antiangiogenic tumor therapies. Cancer Res 2000; 60: 1388-1393.
21. Colleoni M, Rocca A, Sandri M et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factors levels. Ann Oncol 2002; 13: 73-80.
22. Colleoni M, Orlando L, Sanna G et al. Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006; 17: 232-238.
23. Orlando L, Cardillo A, Ghisini R et al. Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastasic breast cancer. BMC Cancer 2006; 6: 225-231.
24. Goldenberg MM: Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. Clin Ther 1999; 21: 309-18.
25. Press MF, Jones LA, Godolphin W et al. HER-2/neu oncogene amplification and expression in breast and ovarian cancers. In Joseph Ragaz (ed): Effects of Therapy on Biology and Kinetics of the Residual Tumor, New York: Wiley-Liss, Inc., Progress in Clinical and Biological Research. 1990; 354A: 209.
26. Revillion F, Bonneterre J, Peyrat JP: ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34: 791-808.
27. Petit AM, Rak J, Hung MC et al. Neutralizing antibodies against epidermal growth factor and erbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo. Angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997; 151: 1523-1530.
28. Laughner E, Taghavi P, Chiles K et al. HER2 (neu) signalling increases the rate of hypoxia-inducible factor 1 alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995-4004.
29. Izumi Y, Xu L, di Tomaso E et al. Herceptin acts as an anti-angiogenic cocktail. Nature 2002; 416: 279-280.
30. Klos KS, Zhou X, Lee S et al. Combined trastuzumab and paclitaxel treatment better inhibits erbB2 mediated angiogenesis in breast carcinoma through a more effective inhibition of AKT than either treatment alone. Cancer 2003; 98: 1377-1385.
31. Koukurakis MI, Simopoulos C, Polychronidis A et al. The effect of trastuzumab/docetaxel combination on breast cancer angiogenesis: dichotomous effect predictable by HIF1a/VEGF pretreatment status? Anticancer Res 2003; 23: 1673-1680.
32. Pegram M, Chan D, Dichmann RA et al. Phase II combined biological therapy targeting the HER2 proto-oncogene and the vascular endothelial growth factor using trastuzumab (T) and bevacizumab (B) as first line treatment of HER2-amplified breast cancer. San Antonio Breast Cancer Symposium 2006: 301.
33. Tonini G, Schiavon G, Silletta M et al. Antiangiogenic properties of metronomic chemotherapy in breast cancer. Future Oncol 2007; 3: 183-90.
34. Esteva FJ, Sahin AA, Cristofanilli M et al. Molecular prognostic factors for breast cancer metastasis and survival. Semin Radiat Oncol 2002; 12: 319-28
35. Rocca A. Metronomic chemotherapy with capecitabine and oral cyclophosphamide in combination with bevacizumab in metastatic breast cancer (mbc): Evidence of activity of an antiangiogenic treatment. J Clin Oncol, ASCO Annual Meeting Proceedings 2007; 18S: 11501
36. Burstein HJ, Spigel D, Kindsvogel K et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. San Antonio Breast Cancer Symposium 2005: 4
37. Munoz R, Shaked Y, Bertolini F et al. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. Breast 2005; 14: 466-79.
38. Wen XF, Yang G, Mao W et al. HER2 signaling modulates the equilibrium between pro- and antiangiogenic factors via distinct pathways: implications for HER2-targeted antibody therapy. Oncogene 2006; 25: 6986-96.
39. García-Sáenz JA, Martín M, Puente J et al. Trastuzumab associated with successive cytotoxic therapies beyond disease progression in metastatic breast cancer. Clin Breast Cancer 2005; 6: 325-329.
40. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006; 355: 2733-43.
41. Sandri MT, Johansson HA, Zorzino L et al. Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy. Cancer 2007; 110: 509-17.
42. Kerbel RS: Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti-cancer therapeutic agents. Bioessays 1991; 13: 31-36.
43. Bottini A, Generali D, Brizzi MP et al. Randomized phase II trial of letrozole and letrozole plus low-dose metronomic oral cyclophosphamide as primary systemic treatment in elderly breast cancer patients, J Clin Oncol 2006; 24: 3623-8.
44. Relf M, LeJeune S, Scout PA, et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963.
45. Folkman J. Angiogenesis in breast cancer. In Bland KI, Copeland EM III (eds): The breast: comprehensive management of benign and malignant disorders, vol. 1, 3rd ed. St. Louis: WB Saunders, 2004: 563.
46. Mancuso P, Colleoni M, Calleri A et al. Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. Blood 2006; 108: 452-459.
47. Scappaticci FA, Skillings JR, Holden SN et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007; 99: 1232-9.
48. Ranieri G, Patruno R, Ruggieri E et al. Vascular endothelial growth factor (VEGF) as a target of bevacizurnab in cancer: from the biology to the clinic. Curr Med Chem 2006; 13: 1845-57.
49. Seidman A, Hudis C, Pierri MK et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20:1215-21.
50. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psychooncology 2007, in press.